Case 2 – A case of secondary platinum-resistant ovarian cancer
Authors
Marilena Di Napoli
Division of Medical Oncology, Department of Uro-Gynecological, Oncology, IRCCS, Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy.
Domenica Lorusso
Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale Tumori, Milano, Italy
advanced ovarian cancer, new biological drugs, quality of life
Abstract
Patients with ovarian cancer relapsing during first-line treatment (refractory) or in the following few months (platinum-resistant) are a very heterogeneous group with various biological tumor behaviors. As this condition is linked to an unfavorable prognosis, the main objective of treatment is to palliate symptoms and preserve quality of life. While traditional chemotherapy may help to achieve this, new biological agents that have been introduced or are under development are expected to improve the quality of life and outcomes for patients with advanced ovarian cancer. This case report describes the clinical history of a 67-year-old woman with bilateral ovarian high grade serous papillary adenocarcinoma with lymph node and omentum metastasis.